Literature DB >> 30648543

The role of Slit2 as a tumor suppressor in thyroid cancer.

Min Ji Jeon1, Seonhee Lim2, Mi-Hyeon You3, Yangsoon Park4, Dong Eun Song4, Soyoung Sim2, Tae Yong Kim1, Young Kee Shong1, Won Bae Kim1, Won Gu Kim5.   

Abstract

Slits, representative axon guidance molecules, and their Roundabout (Robo) transmembrane receptors play roles in the progression of many cancers. We investigated the effects of Slit2 on the proliferation, migration, and invasion of thyroid cancer cells, and on the prognosis of papillary thyroid cancer (PTC). Slit2 overexpression inhibited the proliferation, migration and invasion of thyroid cancer cells by inhibiting transcriptional activity of beta-catenin and regulating Rho GTPase activity. Slit2 knockdown activated the migration and invasion of thyroid cancer cells and transcriptional activity of beta-catenin. Fragment Slit2 treatment inhibited thyroid cancer cell proliferation in a dose dependent manner, and also inhibited migration and invasion. When we evaluated the protein expression of Slit2 in PTCs, 24 of 160 PTCs (15%) were negative for Slit2 protein expression and these patients had significantly increased risk of cervical lymph node metastasis (P < 0.001), distant metastasis (P < 0.001) and recurrence of PTC (P < 0.001). Our findings suggest a role for Slit2 as a tumor suppressor, and also as a novel prognostic and potential therapeutic target for thyroid cancer.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Papillary thyroid carcinoma; Prognosis; Slit homolog 2 protein; Thyroid cancer

Mesh:

Substances:

Year:  2019        PMID: 30648543     DOI: 10.1016/j.mce.2019.01.010

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

1.  Expression of the axon guidance factor Slit2 and its receptor Robo1 in patients with Hirschsprung disease: An observational study.

Authors:  Meng Kong; Tao Zhou; Bo Xiang
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

2.  Expression of NF2 Modulates the Progression of BRAFV600E Mutated Thyroid Cancer Cells.

Authors:  Mi Hyeon You; Min Ji Jeon; Tae Yong Kim; Won Bae Kim; Young Kee Shong; Won Gu Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2019-06

3.  BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.

Authors:  Cong Zhang; Chunrui Bo; Lunhua Guo; Pingyang Yu; Susheng Miao; Xin Gu
Journal:  World J Surg Oncol       Date:  2019-12-16       Impact factor: 2.754

4.  Enhancer RNA SLIT2 Inhibits Bone Metastasis of Breast Cancer Through Regulating P38 MAPK/c-Fos Signaling Pathway.

Authors:  Peng Li; Zhiping Lin; Qianzheng Liu; Siyuan Chen; Xiang Gao; Weixiong Guo; Fan Gong; Jinsong Wei; Hao Lin
Journal:  Front Oncol       Date:  2021-10-15       Impact factor: 6.244

Review 5.  Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer.

Authors:  Won Bae Kim; Min Ji Jeon; Won Gu Kim; Tae Yong Kim; Young Kee Shong
Journal:  Endocrinol Metab (Seoul)       Date:  2020-03

6.  Changes in SLIT2 expression are associated with the migration of human ovarian clear cell carcinoma cells.

Authors:  Cuei-Jyuan Lin; Way-Ren Huang; Chia-Zhen Wu; Ruo-Chia Tseng
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

7.  Aberrant Methylation of SLIT2 Gene in Plasma Cell-Free DNA of Non-Small Cell Lung Cancer Patients.

Authors:  Yujin Kim; Bo Bin Lee; Dongho Kim; Sang-Won Um; Joungho Han; Young Mog Shim; Duk-Hwan Kim
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

8.  A miRNA-clinicopathological nomogram for the prediction of central lymph node metastasis in papillary thyroid carcinoma-analysis from TCGA database.

Authors:  Mingjun Wang; Rongjing Li; Xiuhe Zou; Tao Wei; Rixiang Gong; Jingqiang Zhu; Zhihui Li
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.